Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2002 May;68(5) > Minerva Anestesiologica 2002 May;68(5):445-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,623


eTOC

 

ANTITHROMBIN III IN SEVERE SEPSIS  SMART 2002 Milan, May 29-31, 2002FREEfree


Minerva Anestesiologica 2002 May;68(5):445-8

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Antithrombin III in Sepsis. New evidences and open questions

Ostermann H.

From the University of Munich Grosshadern, Germany


FULL TEXT  


Antithrombin III (ATIII) has been found to be a marker for DIC and to be of prognostic significance in septic patients. Several studies have shown that administration of ATIII in patients with sepsis related DIC is effective in shortening the duration of DIC. Despite a meta-analysis of randomized controlled trials have shown a significant reduction in 28-day mortality, a prospective randomized double-blind placebo-controlled trial failed to show a significant improvement in overall survival. However the concomitant use of heparin, which does not seem to have an additional beneficial effect, may have obscured the efficacy of ATIII. More studies are needed to understand mechanism of action of ATIII and better define patient population that may benefit from ATIII.

top of page

Publication History

Cite this article as

Corresponding author e-mail